Department of Pharmacy, Le Bonheur Children's Hospital, Memphis, TN, USA.
Section of Emergency Medicine, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Children's Hospital Colorado, Aurora, CO, USA.
Clin Toxicol (Phila). 2022 Feb;60(2):243-251. doi: 10.1080/15563650.2021.1946556. Epub 2021 Jul 1.
Mental health disorders and related suicide attempts are increasing in both the adult and pediatric patient populations. Because of the increasing prevalence of mental health disorders, there is increased use of psychotropic medications in adult and pediatric patients, which can pose a risk for potentially adverse pediatric ingestions. The objective was to determine trends and outcomes for pediatric psychotropic medication ingestions reported to the American Association of Poison Control Centers (AAPCC) National Poison Data System (NPDS).
This was a retrospective review of pediatric (≤18 years of age) exposures reported to AAPCC NPDS between January 1, 2009 and December 31, 2018. Single psychotropic medication ingestions of atypical antipsychotics, bupropion, buspirone, clonidine, lithium, methylphenidate, mirtazapine, monoamine oxidase inhibitors (MAOIs), selective norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), trazodone, and tricyclic antidepressants (TCAs) were examined.
Over the 10-year study period, 356,548 pediatric psychotropic medication ingestions were reported to NPDS. SSRI ingestions were the most frequently reported (34%), followed by atypical antipsychotics (17%), and methylphenidate (15%). Unintentional ingestions were most prominent in patients 0-12 years of age (79%), whereas, in patients age 13-18 years, 76% were intentional. SSRI ingestions were asymptomatic in 68% of cases. Clonidine and bupropion ingestions had the highest proportion of moderate and major clinical effects (29 and 25%, respectively). There were 29 deaths: atypical antipsychotics ( = 4), bupropion ( = 10), lithium ( = 1), SNRI ( = 1), SSRIs ( = 7), and TCAs ( = 6); 19 (65%) were in adolescent patients.
SSRIs were the most frequently reported ingestion, while bupropion and clonidine were associated with a high percentage of moderate and major clinical effects. This study demonstrates opportunities for targeted prevention strategies to prevent potentially adverse pediatric ingestions to psychotropic medications.
精神健康障碍和相关自杀企图在成年和儿科患者群体中都有所增加。由于精神健康障碍的患病率不断上升,成年和儿科患者中使用精神药物的情况也有所增加,这可能会导致潜在的儿科药物摄入不良。目的是确定向美国毒物控制中心协会(AAPCC)国家毒物数据系统(NPDS)报告的儿科精神药物摄入的趋势和结果。
这是对 2009 年 1 月 1 日至 2018 年 12 月 31 日期间向 AAPCC NPDS 报告的儿科(≤18 岁)暴露情况进行的回顾性审查。审查了单一精神药物摄入的非典型抗精神病药、安非他酮、丁螺环酮、可乐定、锂、哌甲酯、米氮平、单胺氧化酶抑制剂(MAOIs)、选择性去甲肾上腺素再摄取抑制剂(SNRIs)、选择性 5-羟色胺再摄取抑制剂(SSRIs)、曲唑酮和三环类抗抑郁药(TCAs)。
在 10 年的研究期间,NPDS 共报告了 356548 例儿科精神药物摄入。SSRIs 的报告最为常见(34%),其次是非典型抗精神病药(17%)和哌甲酯(15%)。0-12 岁患者中最常见的是意外摄入(79%),而 13-18 岁患者中,76%是故意摄入。SSRIs 摄入的 68%无症状。可乐定和安非他酮摄入的中度和重度临床效果比例最高(分别为 29%和 25%)。有 29 例死亡:非典型抗精神病药( = 4)、安非他酮( = 10)、锂( = 1)、SNRI( = 1)、SSRIs( = 7)和 TCAs( = 6);19 例(65%)发生在青少年患者中。
SSRIs 是报告最多的摄入药物,而安非他酮和可乐定与较高比例的中度和重度临床效果相关。本研究表明,有机会制定有针对性的预防策略,以防止潜在的儿科精神药物摄入不良。